Short description
Exvastat is an innovative, preclinical-stage pharmaceutical company.
Description
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Cambridge, Cambridgeshire, United Kingdom, Europe
Founded on
January 1, 2016
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$7890 - 12340
Sign in for full access
Investors
Blurry Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Andrew McElroy, David Cavalla